Brief: Knight Therapeutics Inc - Qtrly Revenue $53.3 Million
13/08/2020 14:50
Aug 13 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS REPORTS SECOND QUARTER 2020 RESULTS
* QTRLY REVENUE $53.3 MILLION
* Q2 REVENUE VIEW C$50.8 MILLION -- REFINITIV IBES DATA
* QTRLY EARNINGS PER SHARE $0.13
* Q2 EARNINGS PER SHARE VIEW C$-0.03 -- REFINITIV IBES DATA
* ALL CURRENCIES ARE CANADIAN
Source text for Eikon: ID:nGNX6F5znH
Further company coverage: GUD.TO
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil